On March 17, AstraZeneca announcedPhase IIICALYPSO Study Achieves Positive Results, Aiming toEvaluation of Eneboparatide（AZP-3601）Efficacy and safety in adult patients with chronic hypoparathyroidism (HypoPT). EEneboparatide is AstraZeneca in March 2024Acquired for $1.05 billionAmolyt Pharm Obtains aParathyroid Hormone (PTH) Receptor 1 Agonist。CALYPSO study becomes the first Phase III clinical trial of this drug to reach its primary endpoint, validating its clinical benefits.。Research ResultsDisplay,At 24 weeks,eneboparatideAchieved the primary endpoint with statistical significance in adult patients with HypoPT。Eneboparatide was well tolerated.After the 24-week primary treatment period, all patients extended eneboparatide treatment until 52 weeks.The full efficacy and safety data will be analyzed at 52 weeks.HypoPT is a rare endocrine disorder caused by a deficiency of PTH, characterized by impaired regulation of calcium and phosphate levels in the blood. This physiological dysfunction can lead to clinical manifestations, including adverse effects on the kidneys and bones. HypoPT is one of the largest known rare diseases, affecting more than 200,000 people in the United States and the European Union, with approximately 80% being female.Marc Dunoyer, CEO of Alexion, AstraZeneca Rare Disease, stated: "Patients with HypoPT, a rare endocrine disorder, often face a higher risk of hypercalciuria, osteopenia, and osteoporosis. The results of the CALYPSO study further demonstrate that eneboparatide has the potential to become another treatment option for these patients. We look forward to reviewing the clinical outcomes at 52 weeks to fully define the drug's risk-benefit profile."Copyright © 2025 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
